NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Horse,

Good for you. Glad to see you took advantage of this insane low price.

You worked in a big company before you retired. You know how those big companies would act when they spot a great opportunity.

We all know how CSF1R-I is essential in dealing with immuno-suppressive microenvironment. Today, out of curiosity, I checked out which companies were trying to develop CSF1R-I. I made my predictions even before I did the search that Merck or BPs would form a partnership with any company which had preliminary positive results. Here is what I found for a company from South Korea which is trying to develop triple inhibitors including CSF1R.

Qurient has the technology for the orally available immuno-oncology therapeutic small molecule, targeting selectively Axl, Mer, and CSF1R, originated from the Max Planck Institute of Biochemistry.

The small molecule drug called Q702 is an orally available, selective Axl/Mer/CSF1R triple kinase inhibitor showing significant in vivo activity as monotherapy as well as in combination with anti-PD-1 antibody. Q702 not only modulates innate immune components such as myeloid derived suppressor cell, tumor associated macrophage in tumor micro-environment, but also increases MHC I expression in tumor cell.

Would Merck be interested in anything that can take care of immunosuppressive characteristic resulting from tumor-associated macrophage? Absolutely!

http://qurient.com

http://qurient.com/bbs/content.php?co_id=q702

https://businesswire.com/news/home/20211122006506/en/Qurient-Announces-Collaboration-Agreement-with-MSD-to-Evaluate-Selective-Triple-Inhibitor-Q702-in-Combination-With-KEYTRUDA%C2%AE-pembrolizumab

Then I thought myself that's really interesting. I went to check Amgen. Here is what I found.

It is interesting to see that in collaboration with LifeMax Laboratories, Amgen is trying to develop CSF1R-I by forming a joint venture called AmMaxBio. And the more interesting part is that Amgen just started the p3 trial on Keytruda biosimilar. The combination of this two with the platform from NWBO is the way to cure cancer!

https://gunder.com/en/news-insights/client-news/amgen-partners-with-lifemax-laboratories-in-the-formation-of-ammaxbio-inc

https://ammaxbio.com/amb-051

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
https://clinicaltrials.gov/study/NCT05349643

An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
https://clinicaltrials.gov/study/NCT04731675

A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients
https://clinicaltrials.gov/study/NCT04938180

AmMax Bio Announces Positive Phase 2 Results Demonstrating Proof-of-Concept for the Novel Local Delivery of AMB-05X in Patients with Tenosynovial Giant Cell Tumor (TGCT)
https://biospace.com/article/releases/ammax-bio-announces-positive-phase-2-results-demonstrating-proof-of-concept-for-the-novel-local-delivery-of-amb-05x-in-patients-with-tenosynovial-giant-cell-tumor-tgct-/

FDA Grants Fast Track Designation to AMB-05X in Tenosynovial Giant Cell Tumors
https://onclive.com/view/fda-grants-fast-track-designation-to-amb-05x-in-tenosynovial-giant-cell-tumors

Amgen Initiates Ph 3 Study for Pembrolizumab Biosimilar
https://pearceip.law/2024/05/02/amgen-initiates-ph-3-study-for-pembrolizumab-biosimilar/